Short Interest in Pharma Mar (OTCMKTS:PHMMF) Expands By 9,136.2%

Pharma Mar (OTCMKTS:PHMMF) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 8,682 shares, a growth of 9,136.2% from the August 15th total of 94 shares. Based on an average daily volume of 36 shares, the short-interest ratio is currently 241.2 days. Currently, 0.0% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Zacks Research upgraded shares of Pharma Mar to a “hold” rating in a research report on Monday, June 15th. Chardan Capital upgraded Pharma Mar to a “strong-buy” rating in a research note on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy”.

Pharma Mar Stock Performance

Pharma Mar stock opened at $94.60 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. Pharma Mar has a 52 week low of $77.41 and a 52 week high of $110.40. The company’s 50 day moving average price is $88.67 and its two-hundred day moving average price is $93.95.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.